Caesrean Section RatesNCT07504328
Robson Classification System Monitoring and Auditing Caesrean Section Rates
An observational study of Caesrean Section Rates and Robson Classification, run by Sohag University at 1 site in Egypt.
Trial summary
Robson Classification System Monitoring and Auditing Caesrean Section Rates Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Caesrean Section Rates, Robson Classification
- What is being tested?
- just monitoring and auditing ,so there is no intevention
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Feb 2026to 1 Feb 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: pregnant women at >=28 weeks gestaion age.
Who may be able to join
- All pregnant women delivering at ≥ 28 weeks gestation.
- Singleton or multiple pregnancy.
- Cephalic, Breech, or transverse lie.
Who cannot join
- Gestational age < 28 weeks.
- Intrauterine fetal demises before admission
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Robson Classification System Monitoring and Auditing Caesrean Section Rates in Sohag Governate Hospitals
Robson Classification System Monitoring and Auditing Caesrean Section Rates
- Conditions
- Caesrean Section Rates, Robson Classification
- Being tested
- just monitoring and auditing ,so there is no intevention
- Keywords
- Robson Classification, Caesrean Section Rates
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
just monitoring and auditing ,so there is no inteventionOther
just monitoring and auditing ,so there is no intevention
| Study group | Role | What they receive |
|---|---|---|
| Pregnant Women delivering at>28weeks gestaion | Pregnant Women delivering at>28weeks gestaion (interuterine fetal demises before admission are excluded) Receives: Other: just monitoring and auditing ,so there is no intevention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in overall Caesarean section rate
All eligible deliveries during the study period will be included (total coverage sampling).
Collection of baseline data on mode of delivery. Calculation of CS rate and indications. Classification of women retrospectively into Robson groups. Monthly audit meetings to discuss CS indications per Robson group. Data Collection
Data will be collected using a structured sheet including:
Maternal age Parity Gestational age Onset of labor Fetal presentation Number of fetuses Mode of delivery Indication of CS Robson group Maternal outcome Neonatal outcome
Measured: until 1/february/2027
Secondary outcomes (1)
Cs rate in each Robson group. Change in primary Cs rate. Change in repeat Cs rate. Matenal morbidity. Neonatal outcomes(Apgar,NICU admission)
Cs rate in each Robson group Change in primary Cs rate. Change in repeat Cs rate. Matenal morbidity. Neonatal outcomes(Apgar,NICU admission)
Measured: until 1/february/2027
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2026
- Study start1 Feb 2026
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Caesrean Section RatesStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Tarek Ahmed Zaghlol, Sohag University
- Investigators
- Ahmed Abd El Raheem Ahmed, Study director, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07504328
- Sponsor's protocol ID
- Soh-Med-26-3-11MS
- Status last verified
- Mar 2026
- First submitted
- 18 Mar 2026
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Robson Classification System Monitoring and Auditing Caesrean Section Rates in Sohag Governate Hospitals
- ClinicalTrials.gov ID
- NCT07504328
- Acronym / sponsor ID
- Soh-Med-26-3-11MS
- Conditions
- Caesrean Section Rates, Robson Classification
- Keywords
- Robson Classification, Caesrean Section Rates
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 31 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Robson Classification System Monitoring and Auditing Caesrean Section Rates
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pregnant Women delivering at>28weeks gestaion | – | Other: just monitoring and auditing ,so there is no inteventionPregnant Women delivering at>28weeks gestaion (interuterine fetal demises before admission are excluded) |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- pregnant women at >=28 weeks gestaion age.
Key inclusion criteria (3 listed)
- All pregnant women delivering at ≥ 28 weeks gestation.
- Singleton or multiple pregnancy.
- Cephalic, Breech, or transverse lie.
Key exclusion criteria (2 listed)
- Gestational age < 28 weeks.
- Intrauterine fetal demises before admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| just monitoring and auditing ,so there is no inteventionjust monitoring and auditing ,so there is no intevention | Other | Pregnant Women delivering at>28weeks gestaion |
Primary outcome
Change in overall Caesarean section rate
Time frame: until 1/february/2027
All eligible deliveries during the study period will be included (total coverage sampling). Collection of baseline data on mode of delivery. Calculation of CS rate and indications. Classification of women retrospectively into Robson groups. Monthly audit meetings to discuss CS indications per Robson group. Data Collection Data will be collected using a structured sheet including: Maternal age Parity Gestational age Onset of labor Fetal presentation Number of fetuses Mode of delivery Indication of CS Robson group Maternal outcome Neonatal outcome
1 secondary outcome
Cs rate in each Robson group. Change in primary Cs rate. Change in repeat Cs rate. Matenal morbidity. Neonatal outcomes(Apgar,NICU admission)
Time frame: until 1/february/2027
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmed Abd El Raheem Ahmed study director
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Caesrean Section Rates and Robson Classification, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in overall Caesarean section rate (time frame: until 1/february/2027). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.